MSI2 and B-cell chronic lymphocytic leukemia: Elevated MSI2 expression is considered a biomarker of poor outcome in multiple hematological diseases, such as chronic myeloid leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic lymphocytic leukemia (CLL)14,15,19,51–53.